Itolizumab

Drug Profile

Itolizumab

Alternative Names: Alzumab; Anti-CD6 monoclonal antibody - Biocon/CIMAB; Anti-CD6 monoclonal antibody h-T1; h T1; Humanised anti-CD6 monoclonal antibody ior t1; T12 antibody; T12 monoclonal antibody; T1h; T1hT

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Center of Molecular Immunology
  • Developer Biocon; Biotech Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action CD6 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Phase II Rheumatoid arthritis
  • Phase I Autoimmune disorders; Psoriasis
  • Preclinical Multiple sclerosis

Most Recent Events

  • 29 Aug 2016 Biocon plans a phase I/II trial for Multiple sclerosis in Cuba (RPCEC00000197)
  • 29 Aug 2016 Center of Molecular Immunology plans a phase III trial for Psoriasis in Cuba (RPCEC00000201)
  • 15 Feb 2016 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Australia (IV, SC) (ACTRN12616000138482)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top